Cambridge Nutritional SciencesFRA:RVKA Return-on-Tangible-Equity is -10.50% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 83.62% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cambridge Nutritional Sciences's annualized net income for the quarter that ended in Sep. 2025 was €-0.91 Mil. Cambridge Nutritional Sciences's average shareholder tangible equity for the quarter that ended in Sep. 2025 was €8.71 Mil. Therefore, Cambridge Nutritional Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was -10.50%.
The historical rank and industry rank for Cambridge Nutritional Sciences's Return-on-Tangible-Equity or its related term are showing as below:
FRA:RVKA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -268.92 Med: -15.06 Max: 60.12
Current: 20.13
During the past 13 years, Cambridge Nutritional Sciences's highest Return-on-Tangible-Equity was 60.12%. The lowest was -268.92%. And the median was -15.06%.
FRA:RVKA's Return-on-Tangible-Equity is ranked better than 83.62% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs FRA:RVKA: 20.13
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cambridge Nutritional Sciences Return-on-Tangible-Equity Related Terms
Cambridge Nutritional Sciences Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RVKA vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -10.50% mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Return-on-Tangible-Equity of -10.50% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #124 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 16.4%.
Is Cambridge Nutritional Sciences' Return-on-Tangible-Equity too high?
Cambridge Nutritional Sciences' current Return-on-Tangible-Equity is -10.50%. Based on the distribution chart, Cambridge Nutritional Sciences ranks #124 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #124 out of 757 companies for Return-on-Tangible-Equity. This places Cambridge Nutritional Sciences in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current Return-on-Tangible-Equity is -10.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Cambridge Nutritional Sciences (FRA:RVKA) has a current Return-on-Tangible-Equity of -10.50%. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current Return-on-Tangible-Equity is -10.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Return-on-Tangible-Equity is -10.50% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences Business Description
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 